At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
In Brief
A Phase 3 clinical trial evaluating Paclitaxel + bevacizumab therapy and Paclitaxel + bevacizumab + atezolizumab for Breast Cancer. Completed, enrolled 281 participants across 1 site.
Detailed Summary
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast cancer.
Study Details
Timeline
Interventions
The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met. \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met. \[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV